166480.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.46, which is below the industry median. The company's cash and equivalents amount to 1,230,249,060 KRW, but this is significantly lower than its long-term debt of 38,898,339,890 KRW, resulting in a negative net cash position.
Profitability metrics are negative, with a return on equity of -0.4863 and a return on assets of -0.2388, both of which are below the industry median. The company reported a net loss of 26,833,142,830 KRW, and its operating income was also negative at -26,533,499,620 KRW. These figures indicate a challenging financial performance relative to industry standards.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the risk associated with market-specific downturns or regulatory changes affecting the healthcare diagnostics industry.
The company's growth trajectory is negative, with a reported revenue of 20,158,947,970 KRW. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement expected in the near term. The company's operating cash flow and free cash flow are both negative, at -13,866,551,050 KRW and -24,730,986,570 KRW, respectively, which limits its ability to fund operations and growth initiatives.
The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's financial constraints. The dilution potential is low, but the company's negative cash flows and high debt levels may necessitate future financing, which could lead to share dilution.
Recent events, as disclosed in the company's financial filings, include a significant net loss and negative operating and free cash flows. These events underscore the company's ongoing financial challenges and the need for strategic adjustments to improve its financial health.
- The company has a weak liquidity position, with a current ratio of 0.46.
- Profitability metrics are negative, with a return on equity of -0.4863 and a return on assets of -0.2388.
- The company's revenue is concentrated in a single segment, increasing market-specific risk.
- The company's growth trajectory is negative, with no significant improvement expected in the near term.
- The company faces a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 166480.KQ Market data — financials · 2026-05-26